Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Apr;71(4):868–872. doi: 10.1038/bjc.1995.167

Preoperative serum levels of CEA and CA 242 in colorectal cancer.

M Carpelan-Holmström 1, C Haglund 1, P Kuusela 1, H Järvinen 1, P J Roberts 1
PMCID: PMC2033721  PMID: 7710956

Abstract

Preoperative serum levels of CEA and CA 242 were determined in 260 patients with colorectal cancer and in 92 patients with benign colorectal diseases. The overall sensitivity of the CEA test was 43% and of the CA 242 test 39%. The corresponding specificities were 90% and 87% respectively, using 5 ng ml-1 as cut-off level for CEA and 20 U ml-1 for CA 242. The sensitivity of CEA was 26%, 32%, 38% and 77% for Dukes A, B, C and D colorectal cancer, and the sensitivity of CA 242 was 26%, 26%, 40% and 67%, respectively. The correlation between CEA and CA 242 was low. Concomitant elevation of both markers was seen in 5%, 12%, 18% and 59% of patients with Dukes A, B, C and D colorectal cancer, respectively. Of all the patients, 23% showed elevation of both the CEA and the CA 242 level, whereas CEA alone was elevated in 20% and CA 242 alone in 15% of the patients with colorectal cancer. Combined use of both markers raised the overall sensitivity from 43% to 58%, but reduced the specificity from 90% to 80%. The increase in sensitivity by combining the two markers was most marked in Dukes A, B and C colorectal cancer. Either or both of the markers were elevated in 46%, 46% and 60% of the patients respectively. The clinical value of combining CEA and CA 242 seems very promising and should be further investigated in prospective studies.

Full text

PDF
868

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brümmendorf T., Anderer F. A., Staab H. J., Hornung A., Stumpf E., Kieninger G. Prognostic value of preoperative serum CEA level compared to clinical staging: III. An approach to scoring of prognostic factors in colorectal cancer. J Surg Oncol. 1985 Apr;28(4):263–269. doi: 10.1002/jso.2930280405. [DOI] [PubMed] [Google Scholar]
  2. Del Villano B. C., Brennan S., Brock P., Bucher C., Liu V., McClure M., Rake B., Space S., Westrick B., Schoemaker H. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem. 1983 Mar;29(3):549–552. [PubMed] [Google Scholar]
  3. GOLD P., FREEDMAN S. O. DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES. J Exp Med. 1965 Mar 1;121:439–462. doi: 10.1084/jem.121.3.439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Haglund C., Lundin J., Kuusela P., Roberts P. J. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. Br J Cancer. 1994 Sep;70(3):487–492. doi: 10.1038/bjc.1994.332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Haglund C., Roberts P. J., Jalanko H., Kuusela P. Tumour markers CA 19-9 and CA 50 in digestive tract malignancies. Scand J Gastroenterol. 1992;27(3):169–174. doi: 10.3109/00365529208999944. [DOI] [PubMed] [Google Scholar]
  6. Hall N. R., Finan P. J., Stephenson B. M., Purves D. A., Cooper E. H. The role of CA-242 and CEA in surveillance following curative resection for colorectal cancer. Br J Cancer. 1994 Sep;70(3):549–553. doi: 10.1038/bjc.1994.343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Holmgren J., Lindholm L., Persson B., Lagergård T., Nilsson O., Svennerholm L., Rudenstam C. M., Unsgaard B., Yngvason F., Pettersson S. Detection by monoclonal antibody of carbohydrate antigen CA 50 in serum of patients with carcinoma. Br Med J (Clin Res Ed) 1984 May 19;288(6429):1479–1482. doi: 10.1136/bmj.288.6429.1479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Johansson C., Nilsson O., Baeckström D., Jansson E. L., Lindholm L. Novel epitopes on the CA50-carrying antigen: chemical and immunochemical studies. Tumour Biol. 1991;12(3):159–170. doi: 10.1159/000217701. [DOI] [PubMed] [Google Scholar]
  9. Johansson C., Nilsson O., Lindholm L. Comparison of serological expression of different epitopes on the CA50-carrying antigen CanAg. Int J Cancer. 1991 Jul 9;48(5):757–763. doi: 10.1002/ijc.2910480521. [DOI] [PubMed] [Google Scholar]
  10. Kuusela P., Haglund C., Roberts P. J. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases. Br J Cancer. 1991 Apr;63(4):636–640. doi: 10.1038/bjc.1991.146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kuusela P., Haglund C., Roberts P. J., Jalanko H. Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases. Br J Cancer. 1987 Jun;55(6):673–676. doi: 10.1038/bjc.1987.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Metz C. E. Basic principles of ROC analysis. Semin Nucl Med. 1978 Oct;8(4):283–298. doi: 10.1016/s0001-2998(78)80014-2. [DOI] [PubMed] [Google Scholar]
  13. Minton J., Chevinsky A. H. CEA directed second-look surgery for colon and rectal cancer. Ann Chir Gynaecol. 1989;78(1):32–37. [PubMed] [Google Scholar]
  14. Nilsson O., Johansson C., Glimelius B., Persson B., Nørgaard-Pedersen B., Andrén-Sandberg A., Lindholm L. Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9. Br J Cancer. 1992 Feb;65(2):215–221. doi: 10.1038/bjc.1992.44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Roberts P. J. Tumour markers in colorectal cancer. Scand J Gastroenterol Suppl. 1988;149:50–58. doi: 10.3109/00365528809096956. [DOI] [PubMed] [Google Scholar]
  17. Röthlin M. A., Joller H., Largiadèr F. CA 242 is a new tumor marker for pancreatic cancer. Cancer. 1993 Feb 1;71(3):701–707. doi: 10.1002/1097-0142(19930201)71:3<701::aid-cncr2820710308>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  18. Turnbull R. B., Jr, Kyle K., Watson F. R., Spratt J. Cancer of the colon: the influence of the no-touch isolation technic on survival rates. Ann Surg. 1967 Sep;166(3):420–427. doi: 10.1097/00000658-196709000-00010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Young C. C., Kofoid C. A., Johnstone H. G. Laboratory: The Cultivation of Endameba Gingivalis (Gros) from the Human Mouth. Am J Public Health Nations Health. 1929 May;19(5):549–552. doi: 10.2105/ajph.19.5.549. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES